Physician profile
Corrie Ann Schell
NPI 1508382524
$4,254.09
in general payments reported to CMS, 2019-2025
18 companies · $755 in 2025
The $755 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $866 · 2023: $1,182 · 2024: $1,247 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.80 |
| Education | $316.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $615.02 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $581.71 | 2022-2025 | Tremfya |
| Pfizer INC. | $510.62 | 2021-2025 | |
| Lilly USA, LLC | $483.10 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $413.20 | 2022-2024 | Sotyktu |
| Abbvie INC. | $379.32 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $354.14 | 2021-2024 | Blu-U, Odomzo, Ilumya |
| Amgen INC. | $226.43 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $155.78 | 2023-2025 | |
| Incyte Corporation | $141.01 | 2023-2025 | Opzelura |
| Ucb, INC. | $135.10 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $108.82 | 2022-2023 | |
| Glaxosmithkline, LLC. | $41.15 | 2021 | |
| Amarin Pharma, INC. | $36.09 | 2021 | |
| Madrigal Pharmaceuticals | $23.58 | 2025 | Rezdiffra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $20.38 | 2023 | Idacio |
| Galderma Laboratories, L.P. | $14.98 | 2025 | Nemluvio |
| Novo Nordisk INC | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.